Skip to main content

Table 4 Grade 3/4 adverse events according to dose level and nephrectomy

From: Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

 

Dose level 1

Dose level 2

All

N = 25

Nephrec-tomized

N = 4

Non nephrec-tomized

N = 11

All

N = 15

Nephrec-tomized

N = 3

Non nephrec-tomized

N = 7

All

N = 10

N

N

N

%

N

N

N

%

N

%

Thrombotic microangiopathy (TMA)

0

2

2

13.3

1

1

2

20.0

4

16.0

Thrombocytopenia

0

2

2

13.3

0

1

1

10.0

3

12.0

Elevated ALT and/or AST

0

1

1

6.7

1

1

2

20.0

3

12.0

Abdominal pain

0

1

1

6.7

0

1

1

10.0

2

8.0

Thoracic musculoskeletal pain

0

2

2

13.3

0

0

0

0.0

2

8.0

Hypertension

0

0

0

0.0

1

1

2

20.0

2

8.0

Proteinuria

1

0

1

6.7

0

1

1

10.0

2

8.0

Perianal abscess

1

0

1

6.7

0

0

0

0.0

1

4.0

Seizure

0

1

1

6.7

0

0

0

0.0

1

4.0

Diarrhea

0

0

0

0.0

0

1

1

10.0

1

4.0

Confusiona

0

1

1

6.7

0

0

0

0.0

1

4.0

Fatigue

0

1

1

6.7

0

0

0

0.0

1

4.0

Hypernatremia

0

0

0

0.0

1

0

1

10.0

1

4.0

Post-surgery bleeding

0

0

0

0.0

1

0

1

10.0

1

4.0

Lipase increase

0

0

0

0.0

1

0

1

10.0

1

4.0

Pyelonephritis

0

1

1

6.7

0

0

0

0.0

1

4.0

Hand & foot syndrome

1

0

1

6.7

0

0

0

0.0

1

4.0

Venous thrombosis

0

0

0

0.0

1

0

1

10.0

1

4.0

Vomiting

0

1

1

6.7

0

0

0

0.0

1

4.0

  1. aGrade 4 adverse event